(Q24243962)

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Bias in clinical intervention research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Terlipressin for acute esophageal variceal hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

The role of vasopressin in vasodilatory septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Circulatory function and hepatorenal syndrome in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

7 January 2021

Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

7 January 2021

Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

7 January 2021

Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

7 January 2021

Circadian rhythm of arginine vasopressin in hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005162.PUB2

7 January 2021